New injection shows promise for dialysis patients with hormone imbalance
NCT ID NCT06690242
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This study tested a new drug called MT1013 in 115 adults with chronic kidney disease who are on dialysis and have a condition called secondary hyperparathyroidism (high parathyroid hormone). The goal was to see if the drug could safely lower hormone levels by at least 30%. Participants received either MT1013, an active comparator, or a placebo. The results help determine if MT1013 could be a future treatment option for managing this hormone imbalance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug that boosts red blood cells help anemia in kidney disease?
- Predicting kidney trouble in older adults: a data-driven approach to clearer lab results
- Could delaying kidney implant during heart transplant reduce complications?
- Can a new tablet formulation improve how a kidney disease drug is absorbed?
- New drug aims to reduce kidney damage in chronic disease
- Contrast dye Double-Dose: new study tracks kidney fallout in ICU patients